Next-Generation Sequencing Market worth $29.53 billion in 2030
The report "Next-Generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2030" is projected to grow from USD 14.94 billion in 2025 and to reach USD 29.53 billion by 2030 at a Compound Annual Growth Rate (CAGR) of 14.6% during the forecast period.The growing demand for NGS-based diagnostics and personalized treatments, along with platform enhancements in speed, accuracy, and cost efficiency, is driving widespread use of sequencing in both research and clinical settings. However, the expansion of the market is limited by the high upfront investment required to establish sequencing capabilities.
Browse 1100 market data Tables and 65 Figures spread through 720 Pages and in-depth TOC on "Next-Generation Sequencing Market, By Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Services, Application (Drug Discovery, Diagnostic, Agriculture) - Global Forecast to 2030"
View detailed Table of Content here -https://www.marketsandmarkets.com/Market-Reports/next-generation-sequencing-ngs-technologies-market-546.html
The products segment accounted for the largest share, by offering, in the next-generation sequencing market in 2024.
By offering, the NGS market is segmented into products and services. The products segment accounted for the largest share of the NGS market in 2024. The products segment leads largely due to steady, recurring revenue from consumables, while the high price of NGS instruments also adds meaningful value to product sales. Services remain the second-largest segment in the market.
The sequencing by synthesis technology segment, accounted for the largest share in terms of platform technology, in 2024.
By platform technology, the next-generation sequencing market is segmented into sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and other sequencing technologies. The segment comprising sequencing by synthesis constituted the largest share in 2024. This dominant share is attributed to the extensive use of the technique in genomics, transcriptomics, epigenomics, and metagenomics, thereby increasing its market penetration. The segment comprising ion semiconductor sequencing technologies held the second-largest share.
The sequencing service segment accounted for the largest share in the next-generation sequencing market in 2024.
By service type, the next-generation sequencing market is segmented into sequencing services, presequencing services, bioinformatics and data analysis services, and NGS platform services. Sequencing services held the largest share in 2024, driven by large-scale genomics studies and programs run by governments and private organizations that often rely on established providers for high-throughput needs. Bioinformatics and data analysis services ranked second, supported by the growing volume and complexity of sequencing data.
The diagnostics segment accounted for the largest share of the application segment in 2024.
By application, the next-generation sequencing market is segmented into drug discovery & development, diagnostics, agriculture and animal research, and other applications. In 2023, the diagnostics segment accounted for the largest share of the NGS market. This can be attributed to declining sequencing costs, which have made NGS more accessible for routine diagnostic use in clinical labs and hospitals. Support for large-scale screening programs, such as newborn screening and population genomics projects, has also driven demand for NGS diagnostics.
The academic & research institutes segment accounted for the largest share of the product end user segment in the next-generation sequencing market in 2024.
By end user, the next-generation sequencing market is segmented into academic and research institutes, pharmaceutical and biotechnology companies, clinical and diagnostic laboratories, and other end users. Academic and research institutes held the largest share of the next-generation sequencing market in 2024. This is largely because NGS workflows are flexible and fit a wide range of custom study designs, aligning well with academic research needs. These institutes also lead early adoption of emerging areas such as single-cell sequencing and spatial transcriptomics, which depend on advanced NGS platforms and high consumable usage.
The North American region accounted for the largest share of the NGS market in 2024.
The NGS market is segmented into six major regions, namely North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. North America is the largest regional market for NGS in 2024, while Europe is the second-largest
The large share of North America can be attributed to the region's well-developed healthcare and research infrastructure, which supports the adoption of advanced NGS technologies in clinical and research settings. However, the Asia-Pacific region is estimated to be the fastest-growing segment of the market, owing to infrastructure development in developing countries, large-scale population genomics projects, and expanding collaborations among pharma and biotech companies for NGS testing and analysis.
Key players in the NGS market include Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), QIAGEN (Netherlands), Agilent Technologies, Inc. (US), Revvity (US), Eurofins Scientific (Luxembourg), PacBio (US), Oxford Nanopore Technologies plc. (UK), Takara Bio Inc. (Japan), BGI Group (China), Merck KGaA (Germany), BD (US), 10X Genomics (US), New England Biolabs (US), Promega Corporation (US), Novogene Co., Ltd. (China), LGC Limited (UK), WuXi Biologics (China), MGI Tech Co. Ltd. (China), Tecan Trading AG (Switzerland), Twist Biosciences (US), Azenta US, Inc. (US), GenScript (US), SD Biosensor, Inc. (South Korea), Fulgent Genetics (US), Hamilton Company (US), Zymo Research Corporation (US), NeoGenomics Laboratories (US), and Psomagen (US).
About MarketsandMarkets™
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Next-generation Sequencing Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
